Pacific Biosciences of California, Inc.
HealthcareNASDAQ:PACB · NASDAQ Global Select
-$0.04 today
Vol 4.97M · Avg 6.04M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $56.3M |
| Short-term Investments | $219.7M |
| Receivables | $29.4M |
| Inventory | $51.0M |
| Other Current | $13.2M |
| Total Current Assets | $369.5M |
| PP&E (Net) | $65.2M |
| Goodwill | $317.8M |
| Intangible Assets | $14.1M |
| Long-term Investments | $1.6M |
| Other Non-current | $14.2M |
| Total Non-current Assets | $412.8M |
| Total Assets | $782.4M |
Analysis
Selected assets total $782.4M for Latest. The largest visible component is Goodwill at $317.8M, about 40.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $63.7M +15.1% | $55.4M -69.2% | $179.9M -44.7% | $325.1M -29.4% | $460.7M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $215.8M -35.5% | $334.6M -25.9% | $451.5M +1.0% | $447.2M -23.4% | $583.7M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $35.4M +28.8% | $27.5M -24.8% | $36.6M +94.9% | $18.8M -22.5% | $24.2M | $533.8M | $399.4M | -$1.7B |
| Inventory | $49.3M -16.1% | $58.8M +3.7% | $56.7M +12.5% | $50.4M +104.8% | $24.6M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $10.8M -44.6% | $19.5M +12.3% | $17.3M +5680.0% | $300.0K -40.0% | $500.0K | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $375.0M -24.3% | $495.7M -33.2% | $742.0M -12.9% | $852.1M -22.6% | $1.1B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $65.8M +41.3% | $46.6M -32.5% | $69.0M -15.1% | $81.3M +2.8% | $79.1M | $1.2B | $1.5B | $687.8M |
| Goodwill | $317.8M +0.0% | $317.8M -31.3% | $462.3M +12.8% | $410.0M +0.0% | $410.0M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $15.1M -96.1% | $389.6M -14.8% | $457.0M +11.4% | $410.2M -0.2% | $411.0M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $1.5M | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $8.8M -18.9% | $10.8M -31.0% | $15.7M +16.7% | $13.4M +133.4% | $5.8M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $409.1M -46.5% | $764.8M -23.8% | $1.0B +9.7% | $915.0M +1.0% | $905.8M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $784.1M -37.8% | $1.3B -27.8% | $1.7B -1.2% | $1.8B -12.0% | $2.0B | $13.3B | $11.9B | $10.6B |
| Account Payables | $20.8M +25.2% | $16.6M +10.1% | $15.1M +25.2% | $12.0M +9.3% | $11.0M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $448.0K | $0 -100.0% | $490.0K -73.4% | $1.8M +14.6% | $1.6M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 -100.0% | $13.9M -15.2% | $16.3M -46.4% | $30.5M +177.8% | $11.0M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $32.8M +915.8% | $3.2M -58.9% | $7.8M -95.5% | $175.5M +4127.8% | $4.2M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $54.4M -17.9% | $66.3M -30.2% | $95.0M -63.9% | $263.3M +267.2% | $71.7M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $702.4M +8.5% | $647.5M -27.4% | $892.2M -0.5% | $896.7M +0.1% | $896.1M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 +100.0% | -$25.0M | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $19.9M +236.7% | $5.9M +6.7% | $5.5M +208.2% | $1.8M -92.8% | $25.0M | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | -$55.0M -385.8% | $19.2M -5.2% | $20.3M +1461.6% | $1.3M -99.3% | $198.2M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $724.3M +5.3% | $687.6M -27.6% | $949.7M +0.9% | $940.8M -17.8% | $1.1B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $778.7M +3.3% | $753.9M -27.8% | $1.0B -13.2% | $1.2B -1.0% | $1.2B | $14.7B | $3.7B | $9.6B |
| Common Stock | $302.0K +2.7% | $294.0K +9.7% | $268.0K +18.1% | $227.0K +2.7% | $221.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$2.7B -25.4% | -$2.1B -16.8% | -$1.8B -20.0% | -$1.5B -25.8% | -$1.2B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $457.0K +8.3% | $422.0K +92.7% | $219.0K +104.6% | -$4.8M -338.4% | -$1.1M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $5.3M -98.9% | $506.6M -27.8% | $701.3M +24.6% | $562.9M -28.8% | $791.0M | $9.1B | $7.7B | $3.3B |
| Total Debt | $759.5M +12.9% | $672.4M -28.0% | $933.9M -1.5% | $948.5M -0.7% | $955.4M | $724.2M | $410.6M | $399.4M |
| Net Debt | $695.8M +12.8% | $617.1M -18.2% | $754.0M +21.0% | $623.4M +26.0% | $494.6M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
Butterfly Network, Inc.
NYSE:BFLY
$1.45B
Integra LifeSciences Holdings Corporation
NASDAQ:IART
$1.38B
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
SI-BONE, Inc.
NASDAQ:SIBN
$683.87M
Fulgent Genetics, Inc.
NASDAQ:FLGT
$530.52M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Orthofix Medical Inc.
NASDAQ:OFIX
$376.33M
DarioHealth Corp.
NASDAQ:DRIO
$51.63M
POMDOCTOR Ltd
POM
$12.38M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does PACB have?
Pacific Biosciences of California, Inc. (PACB) reported $63.71M in cash and equivalents in fiscal 2025.
How much debt does PACB carry?
Pacific Biosciences of California, Inc. (PACB) reported $759.46M of total debt, with net debt of $695.75M.
Explore More
Continue the stock analysis
Jump to another research area for this company.